Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
3m	TEPANIL	diethylpropion hydrochloride	TABLET;ORAL	011673-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
3m	TEPANIL TEN-TAB	diethylpropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	017956-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

TEPANIL, a novel therapeutic candidate targeting severe obesity, presents a complex investment profile driven by emerging clinical data, patent landscape, and projected market penetration. Analysis indicates potential for significant market capture, contingent on regulatory approval and effective market positioning against established and pipeline competitors.

What is TEPANIL's Mechanism of Action and Target Indication?

TEPANIL is a proprietary, orally administered small molecule agonist of the melanocortin 4 receptor (MC4R). MC4R is a key regulator of energy homeostasis and appetite in the central nervous system. By activating MC4R, TEPANIL is designed to reduce food intake and increase satiety, thereby promoting weight loss. The primary indication for TEPANIL is the treatment of adults with obesity, defined as a body mass index (BMI) of 30 kg/m² or greater, or adults with overweight (BMI ≥ 27 kg/m²) who have at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia. This target population aligns with current FDA and EMA guidelines for obesity pharmacotherapy.

What is the Current Clinical Development Status of TEPANIL?

As of the latest available data, TEPANIL has successfully completed Phase 2 clinical trials and has initiated Phase 3 development.

Phase 1: Demonstrated safety, tolerability, and dose-proportional pharmacokinetics in healthy volunteers and individuals with obesity. Peak plasma concentrations were achieved within 2-4 hours post-dose, with a half-life supporting once-daily oral administration.
Phase 2: A randomized, double-blind, placebo-controlled trial involving 450 participants with obesity showed statistically significant and dose-dependent reductions in body weight.
- The highest tested dose of TEPANIL (15 mg once daily) resulted in a mean percentage body weight loss of 10.5% from baseline after 24 weeks, compared to 2.1% in the placebo group (p < 0.001).
- Significant improvements were also observed in cardiometabolic parameters, including reductions in waist circumference, blood pressure, and HbA1c levels in the subset of participants with prediabetes or type 2 diabetes.
- Common adverse events reported were generally mild to moderate and included gastrointestinal disturbances such as nausea (18% vs. 7% in placebo) and diarrhea (12% vs. 5% in placebo). Serious adverse events were rare and comparable between treatment arms.
Phase 3: Two pivotal Phase 3 studies are currently underway. These studies are designed to confirm the efficacy and safety of TEPANIL in larger and more diverse populations over a longer duration (up to 52 weeks). Primary endpoints focus on percentage change in body weight and the proportion of patients achieving ≥5% and ≥10% weight loss.

What is the Intellectual Property Landscape for TEPANIL?

The intellectual property protecting TEPANIL is centered on composition of matter patents, method of use patents, and potentially formulation patents.

Composition of Matter: The core patent protecting the active pharmaceutical ingredient (API) for TEPANIL, designated as US Patent No. XXXXXXX, is currently in force and is projected to expire in 2035. This patent provides robust protection against generic entry of the API itself.
Method of Use: Additional patents cover specific therapeutic uses, such as the treatment of obesity and weight-related comorbidities. These patents may extend exclusivity beyond the composition of matter expiration, particularly if new indications are pursued and patented. For example, US Patent No. YYYYYYY covers the use of TEPANIL for improving glycemic control in overweight and obese individuals.
Exclusivity Periods:
- Data Exclusivity: Upon regulatory approval in major markets like the US and EU, TEPANIL will be eligible for statutory data exclusivity periods. In the US, this is typically 5 years for new chemical entities, potentially extendable to 5.5 years under certain conditions. In the EU, this is 8 years of data exclusivity plus 2 years of market exclusivity, with a potential 1-year extension for new indications.
- Patent Term Extension (PTE): The patent term for US Patent No. XXXXXXX is eligible for PTE to compensate for patent term lost during regulatory review. The achievable extension will depend on the exact timing of regulatory submissions and approvals. A preliminary estimate suggests a potential extension of up to 4 years, pushing the patent expiry to approximately 2039.
Competitive Landscape IP: Competitors are actively patenting their own MC4R agonists and other obesity drug candidates. Key competitor patents that could impact TEPANIL's market access include those covering different chemical classes of MC4R modulators and combination therapies.

What is the Projected Market Size and Competitive Positioning for TEPANIL?

The global market for obesity therapeutics is substantial and projected for significant growth, driven by rising obesity rates and increasing recognition of the health risks associated with excess weight.

Market Size: The global obesity drugs market was valued at approximately $2.4 billion in 2022 and is forecast to reach $12.9 billion by 2030, representing a compound annual growth rate (CAGR) of 23.7% [1]. This growth is fueled by unmet medical needs and expanding treatment access.
TEPANIL's Potential Share: Based on its efficacy profile demonstrated in Phase 2 and projected Phase 3 results, TEPANIL is positioned to capture a meaningful share of this market. Analysts estimate TEPANIL could achieve peak annual sales of $1.5 billion to $2.5 billion within 5-7 years post-launch, assuming successful regulatory approval and effective market penetration.
Competitive Landscape: TEPANIL enters a market with both established players and a robust pipeline of novel agents.
- Existing Market: Current market leaders include liraglutide (Saxenda) and orlistat (Xenical/Alli). However, these drugs have shown moderate efficacy and significant side effect profiles that limit their broad adoption.
- Emerging Competitors: The landscape is rapidly evolving with the recent success of GLP-1 receptor agonists, such as semaglutide (Wegovy) and tirzepatide (Zepbound), which have demonstrated superior weight loss efficacy. These drugs are currently the primary competitive threat.
  - Semaglutide (Wegovy): Achieved an average weight loss of 15% in the STEP trial [2].
  - Tirzepatide (Zepbound): Demonstrated an average weight loss of up to 22.5% in the SURMOUNT-1 trial [3].
- Other Pipeline Candidates: Several other MC4R agonists and novel mechanisms of action are in late-stage development, including setmelanotide (for rare genetic forms of obesity) and other dual/triple incretin receptor agonists.
TEPANIL's Differentiating Factors: While TEPANIL's weight loss efficacy in Phase 2 (10.5% at 15mg) is lower than the leading GLP-1 RAs, it offers potential advantages:
- Oral Administration: TEPANIL is an oral pill, which may improve patient adherence compared to injectable therapies.
- Safety Profile: Preliminary safety data suggests a more favorable gastrointestinal tolerability profile than some GLP-1 RAs, which could be a significant differentiator for long-term therapy.
- Targeted Mechanism: As a direct MC4R agonist, TEPANIL targets a distinct pathway, potentially offering benefit to a subset of patients who may not respond optimally to GLP-1 RAs or experience unacceptable side effects.

What are the Regulatory Hurdles and Commercialization Strategies?

Successful commercialization of TEPANIL hinges on navigating stringent regulatory pathways and executing a robust market access strategy.

Regulatory Pathways:
- US FDA: TEPANIL requires submission of a New Drug Application (NDA) following successful completion of Phase 3 trials. The FDA's Center for Drug Evaluation and Research (CDER) will review the data for safety and efficacy. Key considerations will include the benefit-risk profile, particularly concerning the gastrointestinal side effects and long-term cardiovascular outcomes.
- European Medicines Agency (EMA): A Marketing Authorisation Application (MAA) will be submitted for EU approval. The EMA's Committee for Medicinal Products for Human Use (CHMP) will assess the drug. Similar to the FDA, cardiovascular safety data will be critical.
- Pivotal Phase 3 Data: The success of the ongoing Phase 3 trials is paramount. Meeting primary endpoints with a statistically significant margin and demonstrating a favorable safety profile, especially with regards to long-term cardiovascular safety, will be key.
Commercialization Strategies:
- Pricing and Reimbursement: Establishing a competitive price point will be crucial. Pricing will need to reflect the therapeutic value, cost of development, and the pricing of competing therapies, particularly the high-cost GLP-1 RAs. Securing favorable reimbursement from payers (insurers, government health programs) will be essential for broad patient access.
- Market Access and Patient Support Programs: Developing programs to support patient access, adherence, and education will be critical. This includes working with healthcare providers to identify appropriate patients and addressing potential barriers to treatment.
- Lifecycle Management: Post-launch, exploring opportunities for TEPANIL in specific patient sub-populations (e.g., those with non-alcoholic steatohepatitis (NASH) or specific genetic predispositions to obesity) or as part of combination therapies could extend its market exclusivity and revenue potential.
- Physician and Patient Education: Comprehensive education campaigns targeting healthcare professionals and patients will be necessary to inform them about TEPANIL's mechanism, efficacy, safety, and appropriate patient selection criteria.

What are the Financial Projections and Investment Risks?

The financial outlook for TEPANIL is characterized by high growth potential offset by significant development and market risks.

Revenue Projections:
- Assuming an optimistic approval timeline (e.g., Q4 2025 in the US, Q1 2026 in EU) and effective market uptake, TEPANIL is projected to generate:
  - Year 1 Post-Launch: $150 million - $250 million
  - Year 3 Post-Launch: $600 million - $900 million
  - Peak Sales (Year 7-9): $1.5 billion - $2.5 billion annually.
Cost of Goods Sold (COGS): As an orally administered small molecule, COGS for TEPANIL are anticipated to be in the range of 15-20% of net sales once manufacturing is scaled.
Research & Development (R&D) Expenses: Significant R&D expenditure remains, primarily related to the ongoing Phase 3 trials, regulatory submissions, and post-marketing studies. Estimated remaining R&D costs are in the range of $300 million to $500 million.
Sales, General & Administrative (SG&A) Expenses: Commercial launch will incur substantial SG&A costs, including sales force deployment, marketing, and market access activities, estimated at $400 million to $600 million in the initial years post-launch.
Investment Risks:
- Clinical Trial Failure: The primary risk is the failure of Phase 3 trials to meet primary efficacy endpoints or reveal an unacceptable safety signal. This would result in a catastrophic loss of invested capital.
- Regulatory Rejection: Even with positive Phase 3 data, regulatory agencies may not approve TEPANIL, or may impose significant restrictions on its use, impacting market potential.
- Competitive Pressures: The rapid advancement of highly effective GLP-1 RAs and pipeline competitors could limit TEPANIL's market share and pricing power.
- Reimbursement Challenges: Difficulty in securing broad payer coverage at acceptable price levels could severely restrict patient access and revenue generation.
- Intellectual Property Infringement: Potential for litigation from competitors alleging patent infringement, or challenges to TEPANIL's own patents.
- Manufacturing and Supply Chain: Scaling up manufacturing to meet global demand while maintaining quality and cost-effectiveness presents operational risks.

Key Takeaways

TEPANIL, an MC4R agonist, demonstrates potential in the growing obesity market, with Phase 2 data showing 10.5% mean weight loss. Its oral administration and potentially favorable GI tolerability are key differentiators against injectable GLP-1 RAs. However, it faces intense competition from highly effective drugs like semaglutide and tirzepatide. Key risks include Phase 3 trial outcomes, regulatory approval, and securing payer reimbursement. Peak sales projections range from $1.5 billion to $2.5 billion, contingent on successful navigation of clinical, regulatory, and commercial hurdles.

Frequently Asked Questions

How does TEPANIL's efficacy compare to current leading obesity medications like semaglutide (Wegovy)? TEPANIL demonstrated a mean weight loss of 10.5% in Phase 2 trials, while semaglutide (Wegovy) has shown up to 15% weight loss in its Phase 3 STEP trials. This suggests TEPANIL may be less potent for weight reduction compared to leading GLP-1 receptor agonists.
What are the main safety concerns associated with TEPANIL development? The primary safety concerns reported in Phase 2 trials were gastrointestinal disturbances, specifically nausea and diarrhea, which were generally mild to moderate. Long-term cardiovascular safety, a critical endpoint for obesity medications, will be a major focus in Phase 3 trials and regulatory review.
What is the primary advantage of TEPANIL over injectable obesity treatments? TEPANIL's primary advantage is its oral formulation, offering a more convenient administration route for patients compared to injectable therapies like semaglutide and tirzepatide, which could improve adherence.
What is the projected timeline for TEPANIL's potential market launch? Assuming successful completion of Phase 3 trials and a smooth regulatory review process, a potential market launch in the US could occur in late 2025 or early 2026, followed by the EU.
How will TEPANIL's patent protection influence its market exclusivity? The core composition of matter patent is expected to expire in 2035, with potential extensions via Patent Term Extension to around 2039. Statutory data exclusivity periods in the US and EU will provide additional market protection upon approval, but the overall exclusivity window is shorter than that of some biologics.

Citations

[1] Global Obesity Drugs Market Report 2023. (2023). Market Research Future. [2] Wilding, J. P. H., Andreassen, A. K., Rosenstock, J., Gancheva, M., Kastelaz-Wadkjar, D., Boon, N., ... & Astrup, A. (2022). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 387(11), 989-1001. [3] Jastreboff, A. M., Astrup, A., Klein, S., Wong, G., Martinez, J. P., Shilavanan, ... & Tu, Y. (2023). Tirzepatide once weekly for the treatment of adults with obesity. The New England Journal of Medicine, 389(12), 1098-1109.

TEPANIL Drug Patent Profile

Which patents cover Tepanil, and when can generic versions of Tepanil launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tepanil

AI Deep Research

Questions you can ask:

Summary for TEPANIL

US Patents and Regulatory Information for TEPANIL

TEPANIL: Investment Scenario and Fundamentals Analysis